Burning Rock Dx(US:BNR) Jing Ji Guan Cha Wang·2026-02-13 22:51Product Development Progress - The company announced that its self-developed breast cancer NGS companion diagnostic kit has successfully entered the priority review channel of the National Medical Products Administration (NMPA) Medical Device Technology Review Center (CMDE), which may accelerate the approval process for the product in the domestic market [2] Financial Performance - According to the Q2 2025 financial report released on September 8, 2025, the company achieved a revenue growth of 10% year-on-year, with net losses narrowing by 91%. The gross margin improved to 72.8%, indicating significant operational efficiency improvements [3] Stock Performance - On January 5, 2026, the company's stock price experienced a notable increase, rising by 6.71% in a single day, closing at $21.00 per share [4]